Insulet (PODD) Earns Buy Rating from Analysts at Berenberg Bank

Berenberg Bank began coverage on shares of Insulet (NASDAQ:PODD) in a research report report published on Friday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $100.00 price objective on the medical instruments supplier’s stock.

Several other analysts also recently commented on the company. Guggenheim began coverage on Insulet in a research note on Tuesday, April 3rd. They set a buy rating and a $105.00 target price on the stock. ValuEngine upgraded Insulet from a hold rating to a buy rating in a research note on Monday, April 2nd. BidaskClub upgraded Insulet from a buy rating to a strong-buy rating in a research note on Friday, March 23rd. Zacks Investment Research upgraded Insulet from a sell rating to a hold rating in a research note on Tuesday, March 13th. Finally, BMO Capital Markets began coverage on Insulet in a research note on Monday, March 5th. They set an outperform rating and a $90.00 target price on the stock. Seven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Insulet currently has a consensus rating of Buy and a consensus price target of $76.32.

How to Become a New Pot Stock Millionaire

Shares of PODD opened at $86.69 on Friday. The company has a current ratio of 6.24, a quick ratio of 5.85 and a debt-to-equity ratio of 3.57. Insulet has a 12 month low of $38.43 and a 12 month high of $89.63. The firm has a market cap of $5,087.40, a price-to-earnings ratio of -188.46 and a beta of 1.38.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The business had revenue of $130.50 million for the quarter, compared to analysts’ expectations of $125.16 million. During the same quarter in the prior year, the business posted ($0.16) earnings per share. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. equities research analysts expect that Insulet will post -0.29 earnings per share for the current year.

In related news, Director David A. Lemoine sold 641 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total value of $49,235.21. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Bradley A. Thomas sold 3,500 shares of the firm’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $85.00, for a total value of $297,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 28,800 shares of company stock worth $2,412,739 over the last three months. Insiders own 3.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Cerebellum GP LLC bought a new position in Insulet in the 4th quarter worth $122,000. Equitec Specialists LLC bought a new position in Insulet in the 4th quarter worth $145,000. James Hambro & Partners bought a new position in Insulet in the 4th quarter worth $165,000. C M Bidwell & Associates Ltd. bought a new position in Insulet in the 4th quarter worth $188,000. Finally, Diversified Trust Co bought a new position in Insulet in the 4th quarter worth $218,000.

COPYRIGHT VIOLATION WARNING: This piece was first published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://weekherald.com/2018/04/23/insulet-podd-earns-buy-rating-from-analysts-at-berenberg-bank.html.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply